FORM 53-901F

SECURITIES ACT

MATERIAL CHANGE REPORT UNDER
SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

Item 1.	REPORTING ISSUER
	Cardiome Pharma Corp.
	6190 Agronomy Road, 6th Floor
	Vancouver, BC V6T 1Z3
Item 2.	DATE OF MATERIAL CHANGE
	December 2, 2004
Item 3.	PRESS RELEASE
	December 2, 2004 - Vancouver, British Columbia
Item 4.	SUMMARY OF MATERIAL CHANGE
	Cardiome Pharma Corp announced that its independent Data Safety Monitoring Board (DSMB) has recommended that the phase 2 clinical trial OPT-CHF should continue as planned. The randomized, placebo controlled OPT-CHF is evaluating oxypurinol as an add-on treatment for class III-IV Congestive Heart Failure. The recommendation was based on the second of three planned safety analyses of data from patients who have completed the 24 week trial and a review of safety data from all patients currently enrolled in the trial.
Item 5.	FULL DESCRIPTION OF MATERIAL CHANGE
	Cardiome Pharma Corp announced today announced that its independent Data Safety Monitoring Board (DSMB) has recommended that the phase 2 clinical trial OPT-CHF should continue as planned. The randomized, placebo controlled OPT-CHF is evaluating oxypurinol as an add-on treatment for class III-IV Congestive Heart Failure. The recommendation was based on the second of three planned safety analyses of data from patients who have completed the 24 week trial and a review of safety data from all patients currently enrolled in the trial.
	Cardiome's DSMB is composed of independent medical experts who monitor and evaluate the safety of the clinical trial. In order to protect the integrity of the clinical trial, the company remains blinded to the data. OPT-CHF will ultimately enroll 400 patients. The Company expects enrollment to complete by the end of 2004, with results projected to be available in the third quarter of 2005.

Item 6.	RELIANCE ON SECTION 85(2) OF THE SECURITIES ACT (BRITISH COLUMBIA) AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS
	Not Applicable.
Item 7.	OMITTED INFORMATION
	Not Applicable.

Item 8.	SENIOR OFFICER
	Name:                                                        Christina Yip
	Title:                                                          Vice President, Finance and Administration
	Phone No.:                                                604-677-6905

Item 9.	STATEMENT OF SENIOR OFFICER
	The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, British Columbia, this 2^nd day of December, 2004.

CARDIOME PHARMA CORP.
Per:
	Christina Yip, Vice President, Finance and Administration

IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.